ClinicalTrials.gg
Active, not recruitingNCT02263781PHDUpdated Jul 16, 2024

PREPL in Health and Disease

An interventional study of Blood draw and muscle biopsy in Hypotonia-Cystinuria Syndrome, Muscle Hypotonia and Healthy Volunteers, sponsored by Universitaire Ziekenhuizen KU Leuven. Active, not recruiting at 1 site in Belgium. Open to participants aged Up to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
Up to 40 Years
Sex
All
01

Study summary

Evaluation of PREPL activity in healthy controls and known or possible PREPL deficient patients

Read the detailed description

PREPL is defective in hypotonia cystinuria syndrome and in isolated PREPL deficiency. The investigators have constructed a blood test to evaluate PREPL activity in patients with possible PREPL deficiency.

The study will determine normal values for age (0-18) for PREPL activity in blood.

Also, patients with a clinical phenotype that overlaps with PREPL deficiency (including patients with known primary PREPL deficiency and Prader-Willi syndrome) will be evaluated for PREPL activity in blood.

A last part of the study will involve muscle biopsies during elective anesthesia/surgery for other reasons. There will be 2 groups: patients without signs of PREPL deficiency undergoing surgery (controls) and patients with Prader-Willi syndrome undergoing anesthesia or surgery (patients). The control group will be age-matched to the hypotonia group. In the muscle biopsies, PREPL activity and expression will be evaluated.

02

Conditions studied

  • Hypotonia-Cystinuria Syndrome
  • Muscle Hypotonia
  • Healthy Volunteers
  • Dwarfism, Growth Hormone Deficiency
  • Obesity
  • Prader-Willi Syndrome
03

In context

Muscle Hypotonia

66 studies on the registry are indexed under Muscle Hypotonia; 14 are open to participants now.

This study's planned enrollment of 125 is above the median of 49 across 43 interventional studies indexed under Muscle Hypotonia.

Browse Muscle Hypotonia studies →

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • According to group
  • Control group: children seen at a postinfectious consultation

Exclusion criteria

Exclusion Criteria:

  • Control group: symptoms overlapping with PREPL deficiency, genetic or syndromic disease, atypically developing children
  • other groups: for blood draw
  • group with muscle : contra-indication for muscle biopsy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    Control Blood

    Patients on routine postinfectious control, blood draw

    Procedure: Blood draw

  • Experimental
    Primary PREPL deficiency Blood

    Patients with primary PREPL deficiency, blood draw

    Procedure: Blood draw

  • Experimental
    Prader Willi syndrome Blood

    Patients with Prader-Willi syndrome, blood draw

    Procedure: Blood draw

  • Experimental
    Primary PREPL deficiency like Blood

    Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw

    Procedure: Blood draw

  • Experimental
    Control muscle

    Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw

    Procedure: Blood draw · Procedure: muscle biopsy

  • Experimental
    Prader-Willli syndrome muscle

    Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw

    Procedure: Blood draw · Procedure: muscle biopsy

Interventions

  • ProcedureBlood draw

    Blood draw

  • Proceduremuscle biopsy

    Muscle biopsy during planned anesthesia/surgery

06

What researchers measure

Primary outcomes

  1. PREPL activity (ng active PREPL/g protein) normal values in blood

    normal values for PREPL activity

    Time frame: 3 months

  2. PREPL activity in patients with Prader Willi syndrome compared to activity in normal controls

    Comparison of PREPL activity in blood and muscle between above mentioned groups

    Time frame: 3 months

  3. PREPL activity in patients with primary PREPL deficiency compared to activity in normal controls

    Comparison of PREPL activity in blood between above mentioned groups

    Time frame: 3 months

Secondary outcomes

  1. PREPL activity in patients with muscle weakness/obesity/growth hormone deficiency compared to activity in normal controls

    exploratory evaluation

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Publications

  • Regal L, Shen XM, Selcen D, Verhille C, Meulemans S, Creemers JW, Engel AG. PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology. 2014 Apr 8;82(14):1254-60. doi: 10.1212/WNL.0000000000000295. Epub 2014 Mar 7. PubMed 24610330 ↗
  • Jaeken J, Martens K, Francois I, Eyskens F, Lecointre C, Derua R, Meulemans S, Slootstra JW, Waelkens E, de Zegher F, Creemers JW, Matthijs G. Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome. Am J Hum Genet. 2006 Jan;78(1):38-51. doi: 10.1086/498852. Epub 2005 Nov 23. PubMed 16385448 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jan 2025 and a completion of Jan 2025. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Oct 13, 2014
Start
Oct 2014
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02263781
Collaborators
KU Leuven
Responsible party
Sponsor
First posted
Oct 13, 2014
Start date
Oct 2014
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Jul 16, 2024

Study contacts

Luc Régal, MD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion